Paxbp1 is indispensable for the survival of CD4 and CD8 double-positive thymocytes

Front Immunol. 2023 Jun 19:14:1183367. doi: 10.3389/fimmu.2023.1183367. eCollection 2023.

Abstract

The lifespan of double-positive (DP) thymocytes is critical for intrathymic development and shaping the peripheral T cell repertoire. However, the molecular mechanisms that control DP thymocyte survival remain poorly understood. Paxbp1 is a conserved nuclear protein that has been reported to play important roles in cell growth and development. Its high expression in T cells suggests a possible role in T cell development. Here, we observed that deletion of Paxbp1 resulted in thymic atrophy in mice lacking Paxbp1 in the early stages of T cell development. Conditional loss of Paxbp1 resulted in fewer CD4+CD8+ DP T cells, CD4 and CD8 single positive (SP) T cells in the thymus, and fewer T cells in the periphery. Meanwhile, Paxbp1 deficiency had limited effects on the CD4-CD8- double negative (DN) or immature single-positive (ISP) cell populations. Instead, we observed a significant increase in the susceptibility of Paxbp1-deficient DP thymocytes to apoptosis. Consistent with this, RNA-Seq analysis revealed a significant enrichment of the apoptotic pathway within differentially expressed genes in Paxbp1-deficient DP cells compared to control DP cells. Together, our results suggest a new function for Paxbp1, which is an important mediator of DP thymocyte survival and critical for proper thymic development.

Keywords: Paxbp1; apoptosis; development; double-positive (DP) thymocytes; thymus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / genetics
  • CD8-Positive T-Lymphocytes
  • Cell Differentiation / genetics
  • Mice
  • Thymocytes*
  • Thymus Gland* / metabolism

Substances

  • Paxbp1 protein, mouse

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (82103726), Guangdong Basic and Applied Basic Research Foundation (2021A1515011558 and 2023A1515010575), Shenzhen Science and Technology Program (JCYJ20210324110008023), Shenzhen Sanming Project (SZSM201812059), Shenzhen Key Medical Discipline Construction Fund (SZXK040), and Scientific Research Foundation of PEKING UNIVERSITY SHENZHEN HOSPITAL (KYQD2021038 and KYQD2021049).